The Association of Black Cardiologists collaborating with Quantum Genomics’ NEW-HOPE Study, incorporating minority inclusivity, presents Late-Breaking Trial success of novel antihypertensive agent. 

Firibastat meets primary endpoint and demonstrates highly significant and clinically relevant efficacy in lowering blood pressure in a diverse population whose hypertension is typically difficult to treat.  

These results pave the way to a pivotal Phase 3 trial with firibastat in resistant hypertension.